HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis.

AbstractBACKGROUND & AIMS:
Because aldosterone-dependent sodium and water retention contribute to portal hypertension, the safety and effect of an antialdosteronic drug (Kcanrenoate) have been evaluated on the occurrence of de novo appearance of ascites and the development of esophageal varices or the progression of small varices.
METHODS:
Inclusion criteria were as follows: Child-Pugh A viral pre-ascitic cirrhosis, with either F1 esophageal varices or no varices, but endoscopic and/or ultrasound evidence of portal hypertension. Thirteen Italian Liver Units prospectively enrolled 120 patients randomized to receive double-blind either Kcanrenoate (100 mg/day; 66 patients) or placebo (54 patients). Endoscopy and sonography were performed at entry and at 52 weeks unless the patient developed ascites earlier, whereas laboratory examinations were performed at entry and every 3 months thereafter. An intention-to-treat analysis was performed, with each end point assessed by the Fisher exact test; the cumulative risk for the appearance of any end point was analyzed by the adjusted log-rank test (Tarone-Ware), with censoring for drop-outs.
RESULTS:
The progression of variceal status or appearance of ascites, analyzed independently, was not significantly more frequent on placebo (24.1% and 9.2%, respectively) than on Kcanrenoate (12.1% and 1.5%, respectively), whereas the cumulative occurrence of end points was decreased on Kcanrenoate (17.6% vs 38.3% with placebo; P < .05, Tarone-Ware test). The incidence of adverse events was negligible and did not differ between groups.
CONCLUSIONS:
This preliminary study shows that 100 mg/day of Kcanrenoate is well tolerated and does not reduce the individual incidence of ascites and/or the appearance or progression of esophageal varices in preascitc cirrhosis, but may decrease their 1-year cumulative occurrence.
AuthorsLuigi Bolondi, Fabio Piscaglia, Angelo Gatta, Francesco Salerno, Mauro Bernardi, Antonio Ascione, Oscar Ferraù, David Sacerdoti, Stefania Visentin, Franco Trevisani, Roberto Mazzanti, Gabriele Donati, Umberto Arena, Paolo Gentilini, DOC (Decrease Of Complications in cirrhosis) Study Group
JournalClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (Clin Gastroenterol Hepatol) Vol. 4 Issue 11 Pg. 1395-402 (Nov 2006) ISSN: 1542-3565 [Print] United States
PMID16931172 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Mineralocorticoid Receptor Antagonists
  • Canrenoic Acid
Topics
  • Aged
  • Ascites (epidemiology, etiology, prevention & control)
  • Canrenoic Acid (administration & dosage, therapeutic use)
  • Disease Progression
  • Double-Blind Method
  • Esophageal and Gastric Varices (etiology, physiopathology, prevention & control)
  • Female
  • Humans
  • Incidence
  • Kidney Function Tests
  • Liver Cirrhosis (complications, physiopathology)
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: